A PILOT FEASIBILITY STUDY OF INTRACEREBRAL MICRODIALYSIS TO DETERMINE THE NEURO

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 该方案的总体目标是开发一种系统，通过直接确定脑瘤患者是否可以跨越血脑屏障，有效地筛选新的药物，以便在第一和第二阶段脑瘤临床试验中潜在使用。该计划是在脑肿瘤患者接受活组织检查或开颅手术时，在肿瘤或邻近的大脑皮层放置微透析导管。一旦患者从麻醉中恢复并在术后稳定下来，S将被给予一定剂量的全身化疗药物(在这项可行性研究中，将使用已知的跨血脑屏障药物替莫唑胺)，并将进行脑内微透析，以确定透析液中是否有药物恢复，以反映药物穿透血脑屏障的程度。脑瘤间质中的药物水平将与血浆中的水平进行比较。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The overall goal of this protocol is to develop a system for efficiently screening new agents for potential use in Phase I and II brain tumor clinical trials by directly determining if these drugs can cross the BBB in patients with brain tumors. The plan is to place a microdialysis catheter into either the tumor or adjacent cerebral cortex when a brain tumor patient undergoes a biopsy or debulking craniotomy. Once the patient has recovered from the anesthesia and is stable post-operatively, s/he will be given a dose of a systemic chemotherapy agent (in this feasibility study temozolomide, a drug already known to cross the BBB, will be used), and intracerebral microdialysis will be performed to determine if any of the drug is recovered in the dialysate, reflecting the degree to which the drug is able to penetrate the BBB. Drug levels in the brain tumor interstitium will be compared to levels in the plasma.